Business Wire

SOFINNOVA-PARTNERS

Share
Sofinnova Partners Welcomes Mano Iyer as Venture Partner

Sofinnova Partners (“Sofinnova"), a leading European life sciences venture capital firm based in Paris, London, and Milan, announced the appointment of Manohar (Mano) Iyer, a serial entrepreneur with longstanding ties to Sofinnova, as Venture Partner.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230105005045/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Mano Iyer (Photo: Business Wire)

Mr. Iyer will investigate global medical device investment opportunities across the Sofinnova Partners platform of strategies, with a particular focus on helping the firm’s in-house medtech accelerator, Sofinnova MD Start, incubate world-class companies.

Mr. Iyer has more than 25 years of experience in the medical device industry. In 2008, he was a founding member of the original MD Start team that incubated companies including CorWave and LimFlow. He also advised CoreValve, a Sofinnova Capital Strategy portfolio company, which was subsequently purchased by Medtronic for $800 million.

Mr. Iyer founded ReCor Medical during his time as an Entrepreneur-in-Residence at Sofinnova Partners in 2009. ReCor, another Sofinnova Partners investment, which is developing an ultrasound renal denervation system to treat high blood pressure, was successfully sold to Otsuka Medical Devices in 2018. Mr. Iyer left Sofinnova in 2013 to work full-time as the Chief Operating Officer of ReCor.

Antoine Papiernik, Chairman and Managing Partner of Sofinnova Partners, said: “We are delighted to have Mano back in the fold at Sofinnova Partners. He is an experienced company builder and a respected figure in the medical device community who has shown an uncanny ability to start successful companies no matter what condition the global economy is in.”

Anne Osdoit, Partner at Sofinnova Partners, said: “Mano joins us as MD Start is really hitting its stride. Several of our companies are maturing exceptionally well and we have a healthy flow of promising disruptive medtech projects. Mano brings a deep understanding of the sector thanks to his experience and network in the US and Europe. He also knows our medtech acceleration model inside out, having pioneered it with ReCor. We are thrilled to be working with him.”

Mr. Iyer said: “Sofinnova has realized something truly impressive in developing a first-class medtech ecosystem based out of Europe. The firm is recognized globally as an influential player in the space and I’m excited and proud to be back.”

Mr. Iyer started his career in medical devices as an engineer at Arrow International. While at Arrow, he met Tim Lenihan. In 2001, he co-founded Contract Medical International (CMI) with Mr. Lenihan, and ran operations and engineering. CMI specialized in the development and custom manufacturing of minimally invasive medical device systems. It was acquired by Heraeus Group in 2020.

After earning an MBA from Stanford, he joined Sofinnova Partners thanks to an introduction from Gerard Hascoët, whom he had also met while at Arrow. The trio (Hascoët, Lenihan, Iyer) joined forces with Antoine Papiernik and, with the backing of Sofinnova Partners, founded MD Start to create and incubate innovative medical device companies. Now in its third iteration, MD Start is fully integrated into the Sofinnova platform of strategies.

About Sofinnova Partners

Sofinnova Partners is a leading European venture capital firm in life sciences, specializing in healthcare and sustainability. Based in Paris, London and Milan, the firm brings together a team of professionals from all over the world with strong scientific, medical and business expertise. Sofinnova Partners is a hands-on company builder across the entire value chain of life sciences investments, from seed to later-stage. The firm actively partners with ambitious entrepreneurs as a lead or cornerstone investor to develop transformative innovations that have the potential to positively impact our collective future.

Founded in 1972, Sofinnova Partners is a deeply established venture capital firm in Europe, with 50 years of experience backing over 500 companies and creating market leaders around the globe. Today, Sofinnova Partners has over €2.5 billion under management. For more information, please visit: sofinnovapartners.com.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230105005045/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Duco introduces agentic workspace; a new collaboration layer for intelligent operations19.11.2025 10:00:00 CET | Press release

Duco, the trusted control layer in an agentic world, today announced the launch of agentic workspace, a new capability within the Duco Platform designed to help operations teams work alongside intelligent agents with transparency, control and confidence. Agentic workspace is a collaboration environment where users can build, maintain, optimise, manage tasks and exceptions. All within a single, auditable workspace. It brings humans and autonomous agents together in a shared operational context, ensuring interoperability between systems while maintaining full oversight and explainability. “Agentic workspace is the next step in our mission to put people in control of automated operations,” said James Maxfield, Chief Product Officer at Duco. “As firms embrace agentic AI, they need tools that allow them to monitor, adjust and collaborate with these systems in real time. This workspace gives them that control, without slowing innovation.” By combining data automation, exception management an

Quectel Takes Smart Meters to the Next Generation at Enlit 202519.11.2025 10:00:00 CET | Press release

Quectel Wireless Solutions, an end-to-end global IoT solutions provider, has announced it is attending the Enlit 2025 event in Bilbao, Spain on 18-20 November 2025 and will be at Stand 1.G86. Quectel is attending to showcase how its comprehensive range of modules, antennas and services are poised to assist continued massive uptake of smart meters and assist industry moves from first to second-generation devices. With deployments of smart meters, comprised of electricity, water and gas meters, exceeding 1.06 billion at the end of 2023 and set to continue in all regions, according to IoT Analytics, Quectel is seeing growth across all meter types and expansion of meter-based use cases. Smart electricity meters are being deployed in developing markets for the first time and mature markets are accelerating deployments of second-generation smart meters to help users optimize consumption and manage their own power generation via two-way metering communications. Growth is being experienced acr

Pacsun Successfully Implements Manhattan Active® Point of Sale, Unifying Commerce and Cutting Checkout Times19.11.2025 09:00:00 CET | Press release

Manhattan Associates Inc. (NASDAQ: MANH) today announced that Pacsun, a leading youth fashion retailer, has successfully deployed Manhattan Active® Point of Sale (POS), a cloud-native in-store sales and service solution that empowers associates to merge digital convenience with personalised retailing. Following a five-month project start to pilot phase, Pacsun rolled out Manhattan's POS solution across 300 plus stores in just eight weeks. Mobile checkout capabilities eased long in-store lines, while unified inventory management, powered by RFID integration, supported seamless fulfilment across Instagram, Amazon, TikTok and Pacsun’s own channels. During peak holiday season, Pacsun achieved record breaking revenue and streamlined operations, with 40% of online orders being fulfilled via stores, optimising inventory proximity, labour capacity and shipping costs that reduced logistics expenses by 25%. Stores are now critical drivers of retail differentiation, with industry research showing

Frontgrade Gaisler and DELTATEC Enable Advanced Space Computing Across Multiple Missions19.11.2025 09:00:00 CET | Press release

Frontgrade™ Gaisler Technologies a leading provider of high-reliability electronic solutions for space and national security missions, and DELTATEC,a very high-level design house specialized in advanced technologies are pleased to celebrate their successful collaboration in delivering high-performance computing solutions for space applications, with the GR712RC dual-core microprocessor at the heart of several flight-proven systems. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251119011567/en/ The GR712RC, developed by Frontgrade Gaisler and based on the fault-tolerant LEON3FT architecture, has been integrated into multiple Data Handling System (DHS) units designed by DELTATEC. These include one Payload Data Handling Unit (PDHU) and two On-Board Computers (OBCs) currently operating aboard ESA’s eSAIL mission, launched into Low Earth Orbit (LEO) in September 2020. Moreover, DELTATEC recently delivered the Flight Model of the

AGC Biologics and Repair Biotechnologies Partner on Novel mRNA Therapeutic to Combat the Leading Cause of Human Mortality19.11.2025 09:00:00 CET | Press release

Partnership leverages AGC Biologics’ cost-effective and dependable cGMP mRNA and LNP capabilities AGC Biologics today announced it is partnering with Repair Biotechnologies to tackle one of the world's most persistent health challenges and cause of mortality. The collaboration will focus on developing and manufacturing a novel mRNA therapy to rapidly stabilize and reduce the size of atherosclerotic plaques in major blood vessels. Rupture of unstable plaque and subsequent heart attack or stroke is the leading cause of death, accounting for 27% of all human mortality. “Developing a novel mRNA therapeutic as a part of the vital goal of curing atherosclerotic cardiovascular disease is a complex task, and robust manufacturing is critical to our progress,” said Reason, CEO and co-founder, Repair Biotechnologies. “We chose AGC Biologics because they have mastered the entire production chain for therapeutics of this class, eliminating critical risks and delays to provide a fast and reliable pa

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye